GB2102287B - Use of aromatase-inhibitors with antiandrogens for treatment of prostatic hyperplasia. - Google Patents

Use of aromatase-inhibitors with antiandrogens for treatment of prostatic hyperplasia.

Info

Publication number
GB2102287B
GB2102287B GB08213407A GB8213407A GB2102287B GB 2102287 B GB2102287 B GB 2102287B GB 08213407 A GB08213407 A GB 08213407A GB 8213407 A GB8213407 A GB 8213407A GB 2102287 B GB2102287 B GB 2102287B
Authority
GB
United Kingdom
Prior art keywords
aromatase
treatment
prostatic hyperplasia
antiandrogens
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB08213407A
Other languages
English (en)
Other versions
GB2102287A (en
Inventor
Hans-Udo Schweikert
Ulf Tunn
Friedmund Neumann
Theodor Senge
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Schering AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering AG filed Critical Schering AG
Publication of GB2102287A publication Critical patent/GB2102287A/en
Application granted granted Critical
Publication of GB2102287B publication Critical patent/GB2102287B/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
GB08213407A 1981-05-22 1982-05-10 Use of aromatase-inhibitors with antiandrogens for treatment of prostatic hyperplasia. Expired GB2102287B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19813121152 DE3121152A1 (de) 1981-05-22 1981-05-22 "verwendung der kombination eines aromatase-hemmers mit einem antiandrogen zur prophylaxe und therapie der prostatahyperplasie"

Publications (2)

Publication Number Publication Date
GB2102287A GB2102287A (en) 1983-02-02
GB2102287B true GB2102287B (en) 1985-02-27

Family

ID=6133382

Family Applications (1)

Application Number Title Priority Date Filing Date
GB08213407A Expired GB2102287B (en) 1981-05-22 1982-05-10 Use of aromatase-inhibitors with antiandrogens for treatment of prostatic hyperplasia.

Country Status (15)

Country Link
US (1) US4598072A (cg-RX-API-DMAC7.html)
JP (1) JPS57193412A (cg-RX-API-DMAC7.html)
AU (1) AU563785B2 (cg-RX-API-DMAC7.html)
BE (1) BE890522A (cg-RX-API-DMAC7.html)
CA (1) CA1186998A (cg-RX-API-DMAC7.html)
CH (1) CH648211A5 (cg-RX-API-DMAC7.html)
DE (1) DE3121152A1 (cg-RX-API-DMAC7.html)
DK (1) DK354881A (cg-RX-API-DMAC7.html)
FR (1) FR2506158B1 (cg-RX-API-DMAC7.html)
GB (1) GB2102287B (cg-RX-API-DMAC7.html)
IT (1) IT1139175B (cg-RX-API-DMAC7.html)
LU (1) LU83545A1 (cg-RX-API-DMAC7.html)
NL (1) NL8103875A (cg-RX-API-DMAC7.html)
SE (1) SE463074B (cg-RX-API-DMAC7.html)
ZA (1) ZA823501B (cg-RX-API-DMAC7.html)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3607651A1 (de) * 1986-03-06 1987-09-10 Schering Ag Kombination von aromatasehemmer und testosteron-5(alpha)-reduktase-hemmer
US4895715A (en) * 1988-04-14 1990-01-23 Schering Corporation Method of treating gynecomastia
US5372996A (en) * 1989-03-10 1994-12-13 Endorecherche, Inc. Method of treatment of androgen-related diseases
US5364847A (en) * 1989-03-10 1994-11-15 Endorecherche Inhibitors of sex steroid biosynthesis and methods for their production and use
US5595985A (en) 1989-03-10 1997-01-21 Endorecherche Inc. Combination therapy for prophylaxis and/or treatment of benign prostatic hyperplasia
ES2133270T3 (es) * 1989-07-07 1999-09-16 Endorecherche Inc Terapia de combinacion para la profilaxis y/o el tratamiento de hiperplasia prostatica benigna.
JP3350048B2 (ja) * 1989-07-07 2002-11-25 アンドルシェルシュ・インコーポレイテッド アンドロゲン関連疾患の治療方法
DE4001060A1 (de) * 1990-01-16 1991-07-18 Kanoldt Arzneimittel Gmbh Verwendung einer ungesaettigten fettsaeure oder ihrer derivate in der human- und veterinaermedizin und zur herstellung einer arzneimittelzubereitung
TW239145B (cg-RX-API-DMAC7.html) * 1992-05-21 1995-01-21 Endorech Inc
GB2278054A (en) * 1993-05-18 1994-11-23 Zeneca Ltd Compounds for the treatment of urinary incontinence
EP1094798A2 (en) * 1998-03-11 2001-05-02 Endorecherche Inc. INHIBITORS OF TYPE 5 AND TYPE 3 17beta-HYDROXYSTEROID DEHYDROGENASE AND METHODS FOR THEIR USE
DE19825591A1 (de) * 1998-06-09 1999-12-23 Jenapharm Gmbh Pharmazeutische Kombinationen zum Ausgleich eines Testosteron-Defizits beim Mann mit gleichzeitigem Schutz der Prostata
GB9930839D0 (en) * 1999-12-30 2000-02-16 Pharmacia & Upjohn Spa Process for treating gynecomastia
GB0012293D0 (en) * 2000-05-23 2000-07-12 Astrazeneca Ab Pharmaceutical combination
US7001911B2 (en) * 2000-06-28 2006-02-21 Bristol-Myers Squibb Company Fused cyclic modulators of nuclear hormone receptor function
JP2004509072A (ja) * 2000-06-28 2004-03-25 ブリストル−マイヤーズ　スクイブ　カンパニー 選択的アンドロゲン受容体モジュレーター並びにその同定、設計及び使用方法
US20040077605A1 (en) * 2001-06-20 2004-04-22 Salvati Mark E. Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
AU6800101A (en) * 2000-07-05 2002-01-14 Astrazeneca Ab Pharmaceutical combination of an anti-androgen and anastrozole for providing an antiandrogenic effect and aromatase inhibition
GB0016426D0 (en) * 2000-07-05 2000-08-23 Astrazeneca Ab Pharmaceutical combination
WO2002002113A1 (en) * 2000-07-05 2002-01-10 Astrazeneca Ab Pharmaceutical combination of an anti-androgen and letrozole for providing an anit-androgenic effect and aromatase inhibition
US6953679B2 (en) 2000-09-19 2005-10-11 Bristol-Myers Squibb Company Method for the preparation of fused heterocyclic succinimide compounds and analogs thereof
EP1854798A3 (en) * 2000-09-19 2007-11-28 Bristol-Myers Squibb Company Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
US20040087548A1 (en) 2001-02-27 2004-05-06 Salvati Mark E. Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
US6607755B2 (en) 2001-06-21 2003-08-19 Michael Donald Farley Anti-aromatase pharmaceutical composition for controlling testosterone/estrone ratios
SE0103839D0 (sv) * 2001-11-16 2001-11-16 Astrazeneca Ab Pharmaceutical formulation & product
EP1467979B1 (en) * 2001-12-19 2008-08-13 Bristol-Myers Squibb Company Fused heterocyclic compounds and analogs thereof modulators of nuclear hormone receptor function
WO2004058234A2 (en) 2002-12-27 2004-07-15 Schering Aktiengesellschaft Pharmaceutical combinations of phthalazine vegf inhibitors and benzamide hdac inhibitors
ES2628507T3 (es) * 2007-11-13 2017-08-03 Athenion Ag Esteroides C-19 para el tratamiento de la celulitis
WO2010081817A1 (en) * 2009-01-14 2010-07-22 Boehringer Ingelheim International Gmbh Method for treating colorectal cancer
CN106421792A (zh) 2012-02-06 2017-02-22 创新医学概念有限责任公司 包含抗病毒成分和cox‑2抑制剂成分组合的药物组合物及用于药物组合疗法的药盒
EP2762135A1 (en) * 2013-02-04 2014-08-06 Sanofi Methods for reducing the risk of an adverse teriflunomide and rosuvastatin interaction in multiple sclerosis patients
KR20240157117A (ko) * 2014-04-08 2024-10-31 더 메서디스트 하스피틀 iNOS-억제 조성물들 및 이들의 유방암 치료제로서의 용도

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3423507A (en) * 1966-02-25 1969-01-21 Schering Corp Method of treating benign prostratic hypertrophy
US3449494A (en) * 1966-09-29 1969-06-10 Squibb & Sons Inc Anti-inflammatory compositions containing a corticoidal steroid and a testololactone
US4055641A (en) * 1976-05-10 1977-10-25 Richardson-Merrell Inc. Method of treating benign prostatic hypertrophy
DE2817157A1 (de) * 1978-04-17 1979-10-25 Schering Ag Verwendung von antioestrogenen und antigonadotrop wirkenden antiandrogenen zur prophylaxe und therapie der prostatahyperplasie
US4235893A (en) * 1978-05-08 1980-11-25 Brodie Angela M Ester derivatives of 4-hydroxy-4-androstene-3,17-dione and a method for inhibiting estrogen biosynthesis
EP0100566B1 (en) * 1982-07-14 1986-02-19 Akzo N.V. Novel 19-thio-androstane derivatives

Also Published As

Publication number Publication date
CH648211A5 (de) 1985-03-15
IT8123988A0 (it) 1981-09-16
US4598072A (en) 1986-07-01
LU83545A1 (de) 1981-12-01
SE8104624L (sv) 1982-11-23
IT1139175B (it) 1986-09-24
ZA823501B (en) 1983-03-30
FR2506158A1 (fr) 1982-11-26
DE3121152C2 (cg-RX-API-DMAC7.html) 1991-02-07
SE463074B (sv) 1990-10-08
AU563785B2 (en) 1987-07-23
CA1186998A (en) 1985-05-14
BE890522A (fr) 1982-03-29
AU8407582A (en) 1982-11-25
GB2102287A (en) 1983-02-02
DE3121152A1 (de) 1982-12-09
NL8103875A (nl) 1982-12-16
JPS57193412A (en) 1982-11-27
FR2506158B1 (fr) 1986-05-09
JPH0150207B2 (cg-RX-API-DMAC7.html) 1989-10-27
DK354881A (da) 1982-11-23

Similar Documents

Publication Publication Date Title
GB2102287B (en) Use of aromatase-inhibitors with antiandrogens for treatment of prostatic hyperplasia.
DE3476964D1 (en) Cuff equipment for, inter alia, achieving and maintaining fluid- and gas-depleted regions in parts of the body
GB2100601B (en) An aromatase-inhibitor for use in a method of prophylaxis and/or of treatment by therapy of prostatic hyperplasia, and pharmaceutical preparations suitable for such a use.
NZ212067A (en) Derivatives of glycerophosphocholine and glycerophosphoethanolamine; preparation and use
NO813192L (no) Fremgangsmaate til kjemisk behandling av en superlegering med hoeyt wolframinnhold, samt etsemiddel til utfoerelse av fremgangsmaaten
GR3004521T3 (cg-RX-API-DMAC7.html)
ZA889699B (en) Use of polysulfated heparins
NO894222D0 (no) Fremgangsmaater for behandling av profylakse av pneumocytis carinii pneumoni og andre sykdommer og forbindelser og formuleringer til anvendelse i nevnte metoder.
EP0413329A3 (en) 5-methyl-isoxazole-4-carboxylic acid anilides and 2-hydroxyethylidene-cyano acetic acid anilides for the treatment of ocular diseases
DE3468212D1 (en) Monohydroxy-benzoyl peroxide and compositions for treating acne
HU9201045D0 (en) Combined preparation with antitrombotic effect
EP0200156A3 (en) Use of an aqueous solution of a chlorite matrix for treating tumours
ZA849576B (en) 1,7-diphenyl-3-methyllaza-7-cyano-8-methylnonane for use in the treatment of diseases
EP0350738A3 (de) (S)-Emopamil zur Anwendung bei der Behandlung von Migräne
GR77149B (cg-RX-API-DMAC7.html)
DE3373978D1 (en) Composition for the care or treatment of the human skin
PT81801A (en) Process for the treatment of biomass with steam product thereby obtained and its use and reactor
DE3665126D1 (en) Preparation on the basis of a mixture
IL72467A0 (en) New 1,2-diaryl-3-azolylpropane derivatives,their preparation and their use as agents for the treatment of plants
ZA913920B (en) Therapeutic compound
EP0565674A4 (cg-RX-API-DMAC7.html)
ZA884315B (en) Combined use of an antigestagen and a progesterone synthesis inhibitor of the trilostane and epostane type
SG79394G (en) New use of 1.4-dihydropyridine derivatives.
IT1245368B (it) Composto ad attivita' calcioantagonista
BG51097A1 (en) Process for the preparation of radiosensibilizing agent

Legal Events

Date Code Title Description
PCNP Patent ceased through non-payment of renewal fee

Effective date: 19940510